Author:
Azizi Ali,Ogbeni Deborah,Kamuyu Gathoni,Schwartz Lauren M.,Clark Carolyn,Spencer Peter,Bernasconi Valentina
Abstract
AbstractThe CEPI Centralized Laboratory Network implemented key steps in the transfer and monitoring of the developed immunological SARS-CoV-2 assays to ensure standardization across all the facilities of the network. This comprehensive evaluation reinforces the reliability of the generated data and establishes a solid foundation for a standardized approach, enabling precise inter-laboratory comparisons and contributing to the overall integrity of our network’s clinical results. Herein, we will provide a brief elaboration on the specific measures and procedures implemented to standardize the transfer of assays across our network.
Funder
Coalition for Epidemic Preparedness Innovations
Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Azizi, A., Manak, M. & Bernasconi, V. The CEPI centralized laboratory network for COVID-19 will help prepare for future outbreaks. Nat. Med. 29, 2684–2685 (2023).
2. Kumar, A., Bernasconi, V., Manak, M., de Almeida Aranha, A. P. & Kristiansen, P. A. The CEPI centralised laboratory network: supporting COVID-19 vaccine development. Lancet 397, 2148–2149 (2021).
3. Azizi, A. & Bernasconi, V. Unifying global efforts by CEPI’s centralized laboratory network. Front Immunol. 15, 1404309 (2024).
4. Agency, E. M. ICH guideline M10 on bioanalytical method validation and study sample analysis. https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline (2022).
5. FDA, C. Bioanalytical Method Validation Guidance for Industry. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (2018).